FDA Clearance Tracker · K241335
Eversense 365 Continuous Glucose Monitoring (CGM) System
Last checked: Nov 20, 2026Latest source record: Sep 16, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Sep 16, 2024
Substantially Equivalent
Time to decision
126 days
Received May 13, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K241335
- Device name
- Eversense 365 Continuous Glucose Monitoring (CGM) System
- Applicant
- Senseonics, Incorporated
- Applicant location
- Germantown, MD
- Received
- May 13, 2024
- Decided
- Sep 16, 2024
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate (SBA)
- Device class
- Class II
- Regulation
- 21 CFR 862.1357
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code SBA. The earliest in FDA's data is DEN230052, decided Apr 29, 2024.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K241335
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Senseonics, Incorporated
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Eversense AP CGM SystemNew device typeDe Novo
DEN230052 · Decided Apr 29, 2024 · 264 days after receipt
Device type: Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate (SBA) · Laboratory Medicine & Pathology
- Eversense® E3 Continuous Glucose Monitoring (CGM) SystemPMA supplement
P160048-S021 · Decided Mar 29, 2023 · 180 days after receipt · Panel Track
Device type: Sensor, glucose, implanted, non-adjunctive use (QHJ) · Laboratory Medicine & Pathology
- Eversense® E3 Continuous Glucose Monitoring SystemPMA supplement
P160048-S016 · Decided Feb 10, 2022 · 498 days after receipt · Panel Track
Device type: Sensor, glucose, implanted, non-adjunctive use (QHJ) · Laboratory Medicine & Pathology
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.